Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1
18+
5 sites in FL, TX, VA
About this study
This Phase 1 study is focused on people with advanced metastatic cancer. The primary outcome being measured is Assessment of the MTD and/or RP2D (recommended Phase II dose) (Phase 1a).
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Assessment of the MTD and/or RP2D (recommended Phase II dose) (Phase 1a)., Incidence of Treatment-Emergent Adverse Events and dose-limiting toxicities (DLTs) [Safety and Tolerability] of SYS6043 during the study (Phase 1a)
Secondary: B7-H3 protein expression levels, Objective response rate (ORR), SYS6043 Pharmacokinetic
Oncology, Reproductive Health